The Outcome of Philadelphia Chromosome-Positive Adult ALL: Characteristics and Prognosis.
- Author:
Hun Ho SONG
1
;
Je Hwan LEE
;
Byung Min JEON
;
Jung Hee LEE
;
Eul Ju SEO
;
Chan Jeoung PARK
;
Hyun Sook CHI
;
Jung Shin LEE
;
Woo Kun KIM
;
Kyoo Hyung LEE
Author Information
1. Department of Internal Medicine, Hallym University College of Medicine, Chunchon, Korea.
- Publication Type:Original Article
- Keywords:
Adult B-lineage ALL;
Philadelphia chromosome;
Prognosis
- MeSH:
Adult*;
Bone Marrow Transplantation;
Chromosome Aberrations;
Diagnosis;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Hydrogen-Ion Concentration;
Leukocyte Count;
Philadelphia Chromosome;
Platelet Count;
Prognosis*;
Recurrence;
Retrospective Studies;
Survival Rate
- From:Cancer Research and Treatment
2002;34(4):289-295
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The Philadelphia (Ph) chromosome is a well- known chromosome abnormality in adults with B-lineage ALL, and is associated with a poor prognosis. This study compared the clinical manifestations and prognosis in adult Ph-positive and Ph-negative ALL patients. MATERIALS AND METHODS: We retrospectively analyzed the clinical records of adult patients newly diagnosed as B-lineage ALL, between January 1995 and February 2001. Fifty five patients were included in this study. We divided the patients into Ph-positive and Ph-negative groups. RESULTS: Eighteen of the 55 patients (32.7%) were found to have the Ph chromosome. At initial diagnosis, the Ph-positive patients had higher circulating leukocyte counts, lower platelet counts and had a greater tendency to bleed, than the Ph-negative group. The complete remission rates were 83.3% and 83.8% for the Ph-positive and the Ph-negative groups, respectively. Four of the Ph-positive, and 13 of the Ph-negative, patients underwent allogenic bone marrow transplantation. The median follow-up for the surviving patients was 39.3 months. The three-year survival rates were 10.4% and 51.8% for the Ph-positive and the Ph-negative groups, respectively. The median disease-free survival was 7.7 months for the Ph-positive group, but did not reach the median value in the Ph-negative group. Among the Ph-positive patients, age was the only factor that had an impact on the disease outcome. CONCLUSION: In adult B-lineage ALL, the Ph-positive patients had similar complete remission rates to other patients; however, the remission was of shorter duration, with a higher relapse rate in the Ph-positive patients. More effective treatments are needed to improve the survival of the Ph-positive patients.
